ARTICLE | Company News
Tesaro in-licenses Merck's PARP inhibitor
June 9, 2012 1:32 AM UTC
Merck & Co. Inc. (NYSE:MRK) granted Tesaro Inc. (Waltham, Mass.) exclusive, worldwide rights to niraparib (formerly MK-4827), an oral poly(ADP-ribose) polymerase (PARP) inhibitor that has completed a Phase I trial as monotherapy for cancer. The product is also in a Phase I trial in combination with Merck's cancer drug Temodar temozolomide to treat solid tumors. ...